Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
Status:
Active, not recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of rucaparib, a small molecule inhibitor poly (adenosine diphosphate
[ADP]-ribose) polymerase (PARP), being tested in combination with bevacizumab in patients
with recurrent cervical or endometrial cancer. The objective of this study is to determine
the proportion of these patients who survive progression-free for at least 6 months while
receiving this drug combination.